Zacks: Brokerages Anticipate Antares Pharma Inc (NASDAQ:ATRS) Will Post Earnings of -$0.04 Per Share
Equities analysts forecast that Antares Pharma Inc (NASDAQ:ATRS) will post ($0.04) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Antares Pharma’s earnings. The lowest EPS estimate is ($0.04) and the highest is ($0.03). Antares Pharma reported earnings of ($0.03) per share in the same quarter last year, which suggests a negative year over year growth rate of 33.3%. The company is expected to issue its next quarterly earnings results on Tuesday, August 6th.
On average, analysts expect that Antares Pharma will report full-year earnings of ($0.10) per share for the current year, with EPS estimates ranging from ($0.13) to ($0.06). For the next fiscal year, analysts expect that the business will report earnings of $0.18 per share, with EPS estimates ranging from $0.00 to $0.24. Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. Antares Pharma had a negative net margin of 7.91% and a negative return on equity of 17.94%. The firm had revenue of $23.29 million during the quarter, compared to analysts’ expectations of $17.46 million.
In related news, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $2.67, for a total transaction of $80,100.00. Following the completion of the transaction, the director now owns 190,213 shares in the company, valued at approximately $507,868.71. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Leonard S. Jacob sold 92,078 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $3.00, for a total transaction of $276,234.00. Following the transaction, the director now owns 301,970 shares of the company’s stock, valued at approximately $905,910. The disclosure for this sale can be found here. Insiders own 5.49% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Alpine Woods Capital Investors LLC bought a new position in shares of Antares Pharma during the 1st quarter worth approximately $30,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Antares Pharma during the 4th quarter valued at approximately $31,000. Foundations Investment Advisors LLC acquired a new position in Antares Pharma during the 4th quarter valued at approximately $42,000. Virtu Financial LLC acquired a new position in Antares Pharma during the 4th quarter valued at approximately $45,000. Finally, Enterprise Bank & Trust Co acquired a new position in Antares Pharma during the 1st quarter valued at approximately $45,000. Hedge funds and other institutional investors own 42.36% of the company’s stock.
Shares of ATRS traded up $0.04 during mid-day trading on Friday, hitting $2.96. The company’s stock had a trading volume of 653,146 shares, compared to its average volume of 532,703. Antares Pharma has a 52-week low of $2.45 and a 52-week high of $3.96. The stock has a market capitalization of $481.36 million, a PE ratio of -74.00 and a beta of 0.91. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.90 and a current ratio of 2.28.
Antares Pharma Company Profile
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.